Condition: Hypopharyngeal Squamous Cell Carcinoma · Sponsor: Tianjin Medical University Cancer Institute and Hospital
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma. The primary objective is the pathological complete response(pCR)rate following neoadjuvant therapy. The secondary objective includes the major pathological response(MPR)rate following neoadjuvant therapy, the objective response rate (ORR), Organ preservation rate, Surgery postponement rate, event-free survival (EFS), overall survival(OS), and safety.
This description comes directly from the study's public registry record.
Xudong Wang · 86+02223340123-3130 · wxd.1133@163.com
Hongling Wang · 86+02223340123-3130 · wanghongling86@163.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin 300000 | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07665190